Verily Secures $300M, Forges Independent AI Health Path
March 21, 2026, 9:47 pm
Facebook
Location: United States, California, Menlo Park
Verily secured a pivotal $300 million funding round, stepping out from Alphabet's controlling stake. Renamed Verily Health Inc., the company will aggressively expand its AI-native precision health platform. This capital infusion accelerates efforts to harmonize complex healthcare data, generate critical insights, and deploy actionable intelligence across research and clinical workflows. Strategic alliances with industry giants like Samsung and Salesforce amplify its market presence. The crucial shift to independence ensures vendor neutrality, vital for deep integration within the sensitive healthcare sector. Verily aims to revolutionize personalized, predictive medicine for broader impact.
Verily, a leader in healthcare technology, has completed a substantial $300 million funding round. This pivotal investment marks a profound shift for the company. It moves Verily away from Alphabet's direct control. The change establishes Verily as an independent entity. This new phase defines its commitment to AI-driven precision health.
The funding round was led by Series X Capital. This venture fund focuses on scaling moonshot technologies. Alphabet also participated, but its role has changed. Alphabet is now a significant minority investor. It no longer holds a controlling stake. Other key investors include UCHealth and the University of Colorado Anschutz.
This financial milestone coincides with a corporate restructuring. Verily has transitioned its legal structure. It is now Verily Health Inc., a corporation. This formal change underscores its new autonomy. Independence is critical for Verily's future. The healthcare industry demands vendor neutrality. Partners often hesitate to share sensitive data with subsidiaries of large tech giants. This move removes such barriers. Verily can now integrate its technology more deeply. It can collaborate more freely across the medical ecosystem.
Verily's origin lies within Google X, Alphabet's experimental research division. For a decade, it developed technology at the intersection of data science, healthcare, and artificial intelligence. The new capital will accelerate its core mission. Verily seeks to transform multimodal health data. It converts this data into predictive, personalized insights. These insights aim to improve patient outcomes. They also work to reduce healthcare costs.
The company’s AI-native precision health platform is central to its strategy. This platform helps customers harmonize fragmented healthcare data. It generates actionable intelligence. This intelligence can then be deployed across clinical and research workflows. Health systems are often overwhelmed by data. They lack the tools to extract meaningful insights. Verily’s platform addresses this critical bottleneck. It makes healthcare data AI-ready.
Verily offers several key technologies. The Verily Pre platform is a core offering. It helps life sciences companies organize disparate health records. It processes genomic datasets and wearable device information. AI systems then analyze this structured data. The goal is to discover new biomarkers. It also aims to accelerate clinical trials. Another platform is Lightpath. This is an AI-native care management solution. It supports individuals with chronic diseases like diabetes. Verily Me is a health companion application. It provides healthcare advice and recommendations to users.
Commercial momentum is already building for Verily. The company has forged strategic partnerships. One collaboration is with Samsung’s Galaxy Watch. This partnership advances biomarker development. It also supports clinical research through the Pre platform. Another major alliance is with Salesforce. Verily Pre integrates with Agentforce Health. This bridge connects precision medical data with enterprise customer relationship management. These partnerships demonstrate Verily's commitment to broad integration.
Local healthcare providers are also leveraging Verily's expertise. UCHealth and the University of Colorado Anschutz are key partners. They actively use the Verily Pre platform. Their collaboration focuses on AI-powered research. It also drives care transformation. This direct application in clinical settings validates the platform's utility.
Series X Capital’s involvement is strategic. The fund was specifically created to scale promising Google X projects. Gideon Yu, a former executive at Facebook and YouTube, leads the fund. Series X Capital acts as the "last mile of incubation." It helps transition these moonshot projects. The goal is to transform them into financially disciplined, commercially viable enterprises. This partnership provides Verily with critical support. It ensures a strong commercial focus.
Stephen Gillett leads Verily as Chairman and CEO. He emphasizes the company's commitment. It combines clinical and scientific rigor with AI. This approach advances personalized healthcare at scale. The company envisions a future for medicine. It will be predictive, personalized, and proactive. Its mission is to make precision health accessible to everyone.
This new funding empowers Verily. It accelerates its strategic direction. The company is now an independent force. It navigates the complex healthcare landscape with greater agility. Its focus remains on data-driven innovation. By harmonizing health data and applying advanced AI, Verily aims to unlock new possibilities. It strives to improve patient outcomes. It seeks to reduce the burdens on healthcare systems. This new chapter positions Verily as a significant player. It will shape the future of digital health and personalized medicine.
Verily, a leader in healthcare technology, has completed a substantial $300 million funding round. This pivotal investment marks a profound shift for the company. It moves Verily away from Alphabet's direct control. The change establishes Verily as an independent entity. This new phase defines its commitment to AI-driven precision health.
The funding round was led by Series X Capital. This venture fund focuses on scaling moonshot technologies. Alphabet also participated, but its role has changed. Alphabet is now a significant minority investor. It no longer holds a controlling stake. Other key investors include UCHealth and the University of Colorado Anschutz.
This financial milestone coincides with a corporate restructuring. Verily has transitioned its legal structure. It is now Verily Health Inc., a corporation. This formal change underscores its new autonomy. Independence is critical for Verily's future. The healthcare industry demands vendor neutrality. Partners often hesitate to share sensitive data with subsidiaries of large tech giants. This move removes such barriers. Verily can now integrate its technology more deeply. It can collaborate more freely across the medical ecosystem.
Verily's origin lies within Google X, Alphabet's experimental research division. For a decade, it developed technology at the intersection of data science, healthcare, and artificial intelligence. The new capital will accelerate its core mission. Verily seeks to transform multimodal health data. It converts this data into predictive, personalized insights. These insights aim to improve patient outcomes. They also work to reduce healthcare costs.
The company’s AI-native precision health platform is central to its strategy. This platform helps customers harmonize fragmented healthcare data. It generates actionable intelligence. This intelligence can then be deployed across clinical and research workflows. Health systems are often overwhelmed by data. They lack the tools to extract meaningful insights. Verily’s platform addresses this critical bottleneck. It makes healthcare data AI-ready.
Verily offers several key technologies. The Verily Pre platform is a core offering. It helps life sciences companies organize disparate health records. It processes genomic datasets and wearable device information. AI systems then analyze this structured data. The goal is to discover new biomarkers. It also aims to accelerate clinical trials. Another platform is Lightpath. This is an AI-native care management solution. It supports individuals with chronic diseases like diabetes. Verily Me is a health companion application. It provides healthcare advice and recommendations to users.
Commercial momentum is already building for Verily. The company has forged strategic partnerships. One collaboration is with Samsung’s Galaxy Watch. This partnership advances biomarker development. It also supports clinical research through the Pre platform. Another major alliance is with Salesforce. Verily Pre integrates with Agentforce Health. This bridge connects precision medical data with enterprise customer relationship management. These partnerships demonstrate Verily's commitment to broad integration.
Local healthcare providers are also leveraging Verily's expertise. UCHealth and the University of Colorado Anschutz are key partners. They actively use the Verily Pre platform. Their collaboration focuses on AI-powered research. It also drives care transformation. This direct application in clinical settings validates the platform's utility.
Series X Capital’s involvement is strategic. The fund was specifically created to scale promising Google X projects. Gideon Yu, a former executive at Facebook and YouTube, leads the fund. Series X Capital acts as the "last mile of incubation." It helps transition these moonshot projects. The goal is to transform them into financially disciplined, commercially viable enterprises. This partnership provides Verily with critical support. It ensures a strong commercial focus.
Stephen Gillett leads Verily as Chairman and CEO. He emphasizes the company's commitment. It combines clinical and scientific rigor with AI. This approach advances personalized healthcare at scale. The company envisions a future for medicine. It will be predictive, personalized, and proactive. Its mission is to make precision health accessible to everyone.
This new funding empowers Verily. It accelerates its strategic direction. The company is now an independent force. It navigates the complex healthcare landscape with greater agility. Its focus remains on data-driven innovation. By harmonizing health data and applying advanced AI, Verily aims to unlock new possibilities. It strives to improve patient outcomes. It seeks to reduce the burdens on healthcare systems. This new chapter positions Verily as a significant player. It will shape the future of digital health and personalized medicine.